SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (409)3/21/2002 1:06:15 AM
From: Miljenko Zuanic  Read Replies (1) of 496
 
<<Even if unfavorable in onset compared to propofol, there's still a sizable market opportunity for the product esp given such a small market cap for glfd. I think glfd is a very interesting stock at this price.>>

First, what are guaranties that phosphonooxymethyl ethers salt derivatization will work well as prodrug? Second, I am not sure that *unfavorable in onset* will generate market opportunity?

Would like to see some progress with their own R&D staff.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News